Publications by authors named "B E Villegas-Torres"
Article Synopsis
- The study investigates genetic alterations in pediatric B-cell Acute Lymphoblastic Leukemia (B-ALL) in Mexican patients, focusing on their impact on prognosis and treatment.
- A total of 206 patients were analyzed, revealing a notable 21.8% prevalence of specific genetic profiles linked to poorer outcomes and indicating higher risk stratification among the affected.
- The findings suggest that these genetic markers significantly influence overall survival, with variations in mutation frequency compared to other populations, highlighting the need for genomic considerations in treatment strategies.
Case report: A familial B-acute lymphoblastic leukemia associated with a new germline pathogenic variant in . The first report in Mexico.
Front Oncol
March 2024
B-cell acute lymphoblastic leukemia (B-ALL) is one of the most common childhood cancers worldwide. Although most cases are sporadic, some familial forms, inherited as autosomal dominant traits with incomplete penetrance, have been described over the last few years. Germline pathogenic variants in transcription factors such as , and have been identified as causal in familial forms.
View Article and Find Full Text PDFPigmentary mosaicism as a recurrent clinical manifestation in three new patients with mosaic trisomy 12 diagnosed postnatally: cases report and literature review.
BMC Med Genomics
October 2022
Article Synopsis
- Only twenty-one cases of mosaic trisomy 12 have been reported postnatally, with common symptoms including developmental delays and congenital heart defects.
- The study presents three new Mexican patients with distinct phenotypic traits and details unique symptoms, such as specific eye and skin conditions.
- The research provides insights into the cytogenetic and molecular characteristics of these patients, enhancing the understanding of this rare condition and its varied phenotypes.
Background: In Mexico, the incidence of acute myeloid leukemia (AML) has increased in the last few years. Mortality is higher than in developed countries, even though the same chemotherapy protocols are used. CCAAT Enhancer Binding Protein Alpha () mutations are recurrent in AML, influence prognosis, and help to define treatment strategies.
View Article and Find Full Text PDFAcute myeloid leukemia (AML) is the second most frequent leukemia in childhood. The gene participates in hematopoietic stem cell proliferation. mutations are recurrent in AML and influence prognosis.
View Article and Find Full Text PDF